These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10933117)

  • 1. Treatment of childhood-onset schizophrenia with olanzapine.
    Sholevar EH; Baron DA; Hardie TL
    J Child Adolesc Psychopharmacol; 2000; 10(2):69-78. PubMed ID: 10933117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study.
    Mozes T; Greenberg Y; Spivak B; Tyano S; Weizman A; Mester R
    J Child Adolesc Psychopharmacol; 2003; 13(3):311-7. PubMed ID: 14642019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 1-year open-label trial of olanzapine in school-age children with schizophrenia.
    Ross RG; Novins D; Farley GK; Adler LE
    J Child Adolesc Psychopharmacol; 2003; 13(3):301-9. PubMed ID: 14642018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
    Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
    Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manic symptoms induced by olanzapine.
    Lykouras L; Gournellis R; Angelopoulos E
    Eur Neuropsychopharmacol; 2001 Apr; 11(2):97-8. PubMed ID: 11313153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia.
    Kinon BJ; Hill AL; Liu H; Kollack-Walker S
    Int J Neuropsychopharmacol; 2003 Jun; 6(2):97-102. PubMed ID: 12890301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open-label olanzapine treatment in five preadolescent children.
    Krishnamoorthy J; King BH
    J Child Adolesc Psychopharmacol; 1998; 8(2):107-13. PubMed ID: 9730076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents.
    Kumra S; Jacobsen LK; Lenane M; Karp BI; Frazier JA; Smith AK; Bedwell J; Lee P; Malanga CJ; Hamburger S; Rapoport JL
    J Am Acad Child Adolesc Psychiatry; 1998 Apr; 37(4):377-85. PubMed ID: 9549958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divalproex versus olanzapine in mania.
    Vieta E
    J Clin Psychiatry; 2003 Oct; 64(10):1266; author reply 1266-7. PubMed ID: 14658978
    [No Abstract]   [Full Text] [Related]  

  • 11. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine for mixed episodes of bipolar disorder.
    Zullino D; Baumann P
    J Psychopharmacol; 1999; 13(2):198. PubMed ID: 10475728
    [No Abstract]   [Full Text] [Related]  

  • 13. Olanzapine: efficacy in treating the positive and negative symptoms of schizophrenia.
    Gray R
    Ment Health Care; 1998 Feb; 1(6):193-4. PubMed ID: 9791411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New-onset panic attacks in a patient treated with olanzapine.
    Mandalos GE; Szarek BL
    J Clin Psychopharmacol; 1999 Apr; 19(2):191. PubMed ID: 10211927
    [No Abstract]   [Full Text] [Related]  

  • 15. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
    Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
    J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia.
    Kopelowicz A; Zarate R; Tripodis K; Gonzalez V; Mintz J
    Am J Psychiatry; 2000 Jun; 157(6):987-93. PubMed ID: 10831481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of olanzapine as first-line schizophrenia therapy.
    Cohen LJ
    Am J Health Syst Pharm; 1999 Aug; 56(15):1559-60, 1563-4. PubMed ID: 10478999
    [No Abstract]   [Full Text] [Related]  

  • 18. Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia.
    Raskin S; Durst R; Katz G; Zislin J
    J Clin Psychopharmacol; 2000 Oct; 20(5):500-3. PubMed ID: 11001233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine-induced agranulocytosis.
    Naumann R; Felber W; Heilemann H; Reuster T
    Lancet; 1999 Aug; 354(9178):566-7. PubMed ID: 10470705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.